Theranostic pharmacology in PTSD: Neurobiology and timing.

摘要: Recent reviews and treatment guidelines regard trauma-focused cognitive-behavior therapies as the treatments of choice for chronic post-traumatic stress disorder (PTSD). However, many patients do not engage in this when it is available, drop out before completion, or respond. Medications remain widely used, alone conjunction with psychotherapy, although limitations traditional monoamine-based pharmacotherapy are increasingly recognized. This article will review recent developments psychopharmacology PTSD, a focus on current clinical data that apply putative neurobiologic mechanisms to medication use-i.e., theranostic approach. A approach however, also requires consideration timing, pre, peri post trauma underlying dynamic processes affecting synaptic plasticity, HPA axis, hippocampal activation, PFC-amygdala circuitry fear memory.